



D-Pinitol - A Natural Phytomolecule and its Pharmacological effect

Kshama Srivastava^{1*}, Mamta Tiwari¹, Anurag Dubey² and Anubhav Dubey¹

1, Department of Pharmacology, Advance Institute of Biotech and Paramedical Sciences
Kanpur (U.P.) - India

2, Department of Pharmaceutics, Chhatrapati Shahu ji Maharaj University, Kanpur (U.P.) - India

Article info

Received: 11/03/2020

Revised: 30/04/2020

Accepted: 24/05/2020

© IJPLS

www.ijplsjournal.com

Abstract

D-pinitol is a natural compound related to the important family of inositol. It can be found and isolated from many plants, being the active component of ayurvedic remedies from Pinaceae, Asteraceae, Caryophyllaceae, Zygophyllaceae, Cupressaceae, Aristolochiaceae and Sapindaceae. It firstly synthesised and structure characterized from the Sugar pine tree]. D-pinitol is the D-enantiomer of pinitol, it's a 3-O-methyl-D-chiro-inositol. Fortunately, the pharmacological interest in this compound has risen various established multifunctional properties through a variety of signalling pathways: i) anti-cancer, through inhibition of TNF- α and suppression of NF-kB pathway; ii) insulinomimetic and metabolic regulator in type 2 diabetes mellitus, via a post-receptor pathway of insulin action;

iii) antioxidant; iv) hepatoprotective; v) immuno-modulator, balancing Th1/Th2 cytokines; vi) osteoporosis preventive, through p38/JNK and NF-kB pathways; vii) anti-aging, via reduction of the insulin/IGF-1 signalling (IIS) pathway; viii) improver of creatine retention; ix) preventive and ameliorative of Alzheimer's disease through selective γ -secretase modulation. Thus, the present review compresses the literature reported to date in relation to the Pharmacological effects and metabolic pathways of this naturally occurring compound D- Pinitol ingredient providing an extensive guide for a future utilization of all of its potentialities. The result came out from the compilation of data brings up with the conclusion i.e. the d-pinitol is the immerging phytomolecule which possess various pharmacological activity and therapeutic potency toward various diseases which makes this molecule as a choice of drug in future for the control of various enlisted disease.

Keywords: d-pinitol, inositol, cyclitols, anti-cancer, anti-diabetic, antioxidant, osteoporosis

Introduction

D-pinitol is pharmacologically active compound occur naturally generally belongs to the important family of inositol, they are generally cyclitol a cyclic polyol, Pinitol is a (3-O-methyl-D-chiro-inositol) [1,2]. Its name comes from "pine" since it was isolated and identified from the heartwood of *Pinus monticola* for the first time. It is naturally existing compound which was found & isolated from various plants, and it was firstly identified in "Sugar pine" [3]. It can also isolate from synthetic

and semi-synthetic method by the mean of various process such as chemical and biochemical transformations [4,5]. D-Pinitol possess many therapeutic properties such as - 1) Ant diabetic; 2) Anti-inflammatory activity; 3) Antioxidant 4) Hepatoprotective; 5) Immuno-modulator; 6) Anticancer; vii) Anti-osteoporosis.

***Corresponding Author**

Email: kshamasrivastava8@gmail.com

Structure and properties

D-pinitol is a compound generally occurs in nature. It firstly synthesised and structure


characterized from the Sugar pine tree [6]. D-pinitol is the D-enantiomer of pinitol, it's a 3-O-methyl-D-chiro-inositol [7].

Table 1. Properties of drug

S.No.	Properties	Description
1.	Chemical Name	3-O-methyl-D-chiro-inositol [7]
2.	IUPAC Name	(1S,2S,4S,5R)-6-methoxycyclohexane-1,2,3,4,5-pentol [8-12].
3.	Molecular Formula	C ₇ H ₁₄ O ₆
4.	Molecular Weight	194.18g/mol

Chemical Properties

Table 2. Chemical Properties



S.No.	Properties	Description
1.	Colour	white to off-white [13]
2.	Solubility	water and slightly soluble in ethanol [14]
3.	Melting Point	186–187 °C [13]
4.	Boiling Point	317.2+ 42.0 °C at 760mmhg [14]

Sources

Natural

D-pinitol and cyclitols can be commonly found in most plants as a group [15,16,17], Due to the side effects of several allopathic drugs and the increase of resistance to currently used drugs canalized people to use plant materials in the treatment of several diseases. It is reported that more than 80,000 plants have exhibited medicinal property among 250,000 plant species, all over the World

[18]. However, members of the Leguminosae family are the major natural source of this compound [14,16,19,20,21,22] And the pinitol was found from many other families Pinaceae, Asteraceae, Caryophyllaceae, Zygophyllaceous, Cupressaceae, Aristolochiaceae and Sapindaceae [14,22]




Fig. 1: Distribution of d-Pinitol among various families


Table 3: Various source of d-pinitol

Plant Name	Family	Part	Reference
Acer oblongum	Aceraceae	Leaves	23
Aristolochia macrophylla	Aristolochiaceae	leaves	24
Aristolochia gigantean	Aristolochiaceae	leaves	25
Aristolochia arcuata.	Aristolochiaceae	leaves	26
Aristolochia contorta	Aristolochiaceae	Fruits	27
Artemisia dracunculus	Asteraceae	Fruits	28
Artemisia giraldii	Asteraceae	Aerial parts	29
Artemisia vulgaris L.	Asteraceae	Aerial parts	30
Cardiospermum halicacabum, Linn	Sapindaceae	leaves	31
Cordia boisieri	Boraginaceae	fruit	32
Cryptomeria japonica D. Don	Cupressaceae	Heart wood, Sap wood	33
Dianthus barbatus cv.	Caryophyllaceae	Aerial parts	34
Dianthus caryophyllus	Caryophyllaceae	Leaves	35
Fagonia indica	Fagonia indica	Aerial parts	36
Ginkgo biloba L.	Ginkgoaceae	Grains	37
Gnaphalium pellitum	Asteraceae	Flowers	38
Gnaphalium pellitum	Asteraceae	Flowers	39
Honckenya peploides (L.)	Caryophyllaceae	Aerial parts	40
Horse chestnut (Aesculus hippocastanum)	Sapindaceae	pericarp	41

Limonium gmelini	Limonium gmelini	leaves and root	41
Lychnis coronaria L	Caryophyllaceae	Leaves	43
mangrove fernAcrostichumspeciosum	Ceratopteridaceae Rhizophoraceae	Leaves	44
Petiveriaalliacea L	Phytolaccaceae	Fruit	45
Phyllocladustrichomanoides	Podocarpaceae	Heart wood	46
Pterodenapparicioi	Leguminosae Wood	Wood	47
Rhamnellagilgitica	Rhamnaceae	Hard wood	48
Rhizophora apiculata Bl	Rhizopharaceae	Roots	49
Sarcophytesanguinea.	Sarcophytaceae	Different parts	50
Sequoia gigantea.	Cupressaceae	Heart wood	51
Sequoia sempervirens.	Cupressaceae	Heart wood	52
Tribulus cistoides	Zygophyllaceae	Aerial parts	53
Tribulus cistoides	Zygophyllaceae	Root	54
Tribulus macropterusBoiss.	Santaraceae	whole parts	55
Zanha Africana	Sapindaceae	Root bark	56
Zanha Africana	Sapindaceae	Root bark	57

Synthetic


Ley et al. [58] reported the first synthetic method for the preparation of pinitol, who accomplished the preparation of D-pinitol in 35% overall yield starting from benzene (compound 2 in Scheme 1), involving the microbial oxidation of this compound to (1R,2S)-cyclohexa-3,5-diene-1,2-diol (3) followed by 5 synthetic steps (see Ley et al., 1987 for details). Later, these authors improved the strategy to achieve a 49% overall yield [5].



Source 1: Synthesis of D-pinitol (1) from benzene (2)

Hudlicky et al. [4,59] reported a similar methodology starting from microbial oxidation of bromobenzene (compound 4 in Scheme 2) to

(1S,2S)-3-bromocyclohexa-3,5-diene-1,2-diol (5). Later on, Aceña et al. [60] reported the throughout synthesis of D-pinitol initiating from chiral accessible building blocks in seven synthetic steps with a 10% yield.



Source 2: Synthesis of D-pinitol (1) from bromobenzene (4)

Mechanism of action of d-pinitol

The translocation of GLUT4 from the endoplasmic reticulum to the plasma membrane of skeletal muscle is a major target of insulin to maintain the glucose homeostasis [61]. Treatment with 1 mM D-pinitol increased glucose uptake in vitro in L6 myotubes, and induced the GLUT4

translocation to the plasma membrane both in vitro and ex vivo [62].

However, the insulin mimetic effect of D-pinitol was not as prominent as expected according to previous in vivo studies[63]; such differences may be due to the variability between these models and timing of administration of D-pinitol prior to glucose intake.

In fact, more recent studies performed by the same group on a C57BL/6 mice in vivo model demonstrated that the oral administration of 1 g/kg bw (body weight) of D-pinitol 30 min before 1 g/kg bw of glucose increased the membrane translocation of GLUT4 in the skeletal muscle and reduced the plasmatic levels of glucose and insulin [64].




Fig. 2.Suggested mechanism of action of D-pinitol as insulin sensitizer

Source 3.Sanz, M. L.; Martínez-Castro, I.; Moreno-Arribas, M. V. (2008). "Identification of the origin of commercial enological tannins by the analysis of monosaccharides and polyalcohols". Food Chemistry. 111 (3): 778.

Pharmacological Effects of D-pinitol

D-pinitol is reported as a principal compound found in various soy foods and legumes [65,66]. This naturally occurring inositol shows much higher pharmacological potential because of its multifunctional properties (e.g., inositol phosphoglycans generated from lipid and or protein precursors in cell membranes act as

insulin-like factors in vitro and in vivo) [65,67-71].

Antidiabetic

Non-insulin dependent (Type 2) Diabetes Mellitus (T2DM) is a chronic disease with associated comorbidities. Nowadays, it is estimated that every year 6.8% of the world's population die due to this illness [72,73]. As a result of the growing on D-pinitol for the treatment of diabetes mellitus and for the pathologies associated to this disease, there are a number of patents protecting these potential exploitations. For example, an international patent was developed by Rademacher Group Ltd.,[74] to defend uses of D-pinitol as an equivalent of inositol phosphoglycans, for different pathologic conditions (e.g., T2DM and obesity). Additionally, specific uses of compositions containing D-pinitol for treating T2DM and related health complications were claimed in USA., by the University of Washington [75] and by the University of Virginia [76], as well as in Korea by Solgent Co. Ltd. [77,78] and by Amicogen Co. Ltd. [79]. Dang et al. [80] demonstrated that the effectiveness of D-pinitol is related to the ability of this compound to stimulate the mobility of Glucose Transporter 4 (GLUT4), which according to its sensitivity to insulin, plays an important role in the regulation of glucose transportation to the skeletal muscle and the adipose tissue. PI3K/Akt signalling pathway is involved in this process through a protein phosphorylation cascade. Therefore, D-pinitol triggers a reduction of plasma glucose levels under certain conditions of high glucose levels. In concordance, Gao et al. [67] pointed out that the amelioration of insulin resistance in T2DM promoted by D-pinitol occurred through the PI3K/Akt pathway, similarly to other inositol phosphates, implicating the PI3Kp85 and PI3Kp110 subunits [81-83]. Thus, the PI3K/Akt pathway that is implicated in a number of human diseases including cancer, diabetes, cardiovascular and neurological diseases [84], is regulated by D-pinitol, resulting in an effective reduction of the concentration of blood glucose through promotion of glycogen synthesis [85].

Anticancer

Breast cancer represents an enormous public health problem nowadays. Thus, for example, it is

the principal cause of mortality and the most frequent cancer in women in the U.S. [86-89]. On the other hand, prostate cancer that is at epidemic proportions, is particularly dangerous because it has a very high tendency to metastasize, particularly to the bone [90-93]. More specifically, it has been demonstrated that prostate cancer expands to distant organs including the liver, bladder, bone, lungs, spine and lymph nodes [94-96]. In this context, the National Cancer Institute (NCI) has highlighted a number of foods for which there are evidences of a reduced risk of suffering cancer if incorporated in the regular diet, including plant-derived foods such as soybean (51a and b). It has been discovered that D-pinitol reduces the progress and attack of certain prostate cancer cells in vitro at non-cytotoxic concentrations [93,94]. Also, D-pinitol has demonstrated preventive efficacy against breast cancer induced in rats [97,98] as well as tumour-growth inhibitory activity through the modulation of the balance between inflammatory cytokines, hormones, tumour markers, lipids and other biochemical processes [99,100], finally resulting in the growth retardation of tumour cells [101].

The mode of action of the D-pinitol to exert its anti-cancer biological activity has been suggested to be the active blocking of the Nuclear Factor kappa B (NF- κ B) pathway, a transcription factor inactively present in the cytoplasm that is activated through its reallocation to the nucleus by an important number of carcinogens and inflammatory agents [101]. In addition, Lin *et al.* [102,103] found that D-pinitol diminishes in a dose-dependent manner the Focal adhesion kinase (FAK protein) phosphorylation, precisely this is of high interest for treating cancer because FAK is involved in tumour migration and invasion [102,104,105]. Specifically, it has been proven that D-pinitol inhibits cell motility in human prostate cancer cells via the FAK/c-Src signalling pathway [102].

Antioxidant

Oxidative stress has been reported as one of the major causes of tissue damage. Excessive production of free radicals resulting from oxidative stress can damage macromolecules. Increase in malondialdehyde (MDA) is an indicator of oxidative stress [106]. Due to the close relationship that exists between oxidative

stress and altered immune functions, increases in the incidence of autoimmune diseases, higher susceptibility to infections, and accentuated prevalence of carcinogenesis phenomena. Sivakumar *et al.* recently demonstrated the beneficial effect of D-pinitol against oxidative stress [107,108]. The results of the study suggested that D-Pinitol protects the pancreatic tissue from free radical-mediated oxidative stress in addition to its antidiabetic property [107]

Hepatoprotective

D-pinitol exerts a protective effect of the hepatic, kidney and pancreatic tissues against oxidative stress [107,108]. Special mention is given here to the hepatoprotective action because of the importance of the liver as a vital organ, with critical functions such as for example the detoxification of the body from hazardous substances. Unfortunately, a number of reactive species, including free radicals, can damage the liver leading to jaundice, cirrhosis or fatty liver, to name a few. Additionally, viral hepatitis is considered a major health problem throughout the world [109]. Zhou *et al.* [110] Proves that D-pinitol shows a protective effect against human viral hepatitis caused by D-galactosamine (GalN) in rat model. Choi *et al* [71] evidenced that inositol improves the liver function by lowering the levels of certain serum aminotransferases, such as aspartate transaminase (AST) and alanine transaminase (ALT).[71]

Immuno-suppressor

A proper function of the immune system is of very important. Immunodeficiency may occur as a result of certain diseases (e.g., HIV/AIDS/CANCER). A hyperactive immune system leads to serious health problems or autoimmune diseases such as rheumatoid arthritis, type 1 diabetes or lupus erythematosus, to name a few. Asthma, chronic inflammatory processes and a propensity for allergic responses are also the manifestation of a hyperactive immune system [111]. Thus, D-pinitol administration in rats showed very good anti-inflammatory activity, demonstrated by means of the adequate models of chronic inflammation, such as the induction with carrageenan and cotton pellets [112], as well as a remarkable inhibitory capacity of asthma [113]. Thus, Lee *et al.* [113,114] found that D-pinitol reduced the increased levels of the Th2 cytokine

IL-4, a result corroborated by Chauhan et al. [115].

Anti-osteoporosis

Bone is a complex tissue made of different types of cells which are continuously experiencing a range of equilibrated processes of formation and resorption. Osteoporosis results from an imbalance between these processes of bone resorption and bone formation leading to a net bone lost. This imbalance can be originated as a consequence of several conditions such as hormonal disturbances or certain diseases or medications (e.g., corticosteroids or anti-epileptic agents) [68,116]. Drugs for treating osteoporosis (e.g., bisphosphonates, calcitonin and oestrogen) act by inhibiting the function of osteoclasts that are responsible for bone resorption [68,117]. Unfortunately, these drugs have limited success on recovering bone mass (maximum 2% per year) [68]. In this concern, Liu et al. [68] showed that D-pinitol is capable to inhibit the formation of osteoclasts induced by RANKL. Specifically, this inositol exerts this effect through the p38/JNK and NF- κ B pathways. In conclusion, D-pinitol has potential to be used for treatment and prevention of osteoporosis [118].

Anti-aging

Aging can be viewed as an accumulation of changes over time, accompanied with a functional and reproductive decline that is associated with an increased mortality [119,120]. D-pinitol is one of a few compounds known to be capable to mimic DR. Thus, Hada et al. [120] showed that D-pinitol treatment considerably extended life span of *Drosophila melanogaster*, reducing oxidative stress and improving health, with evident benefits in locomotion. Worth noting, no reduction in fecundity was observed. These authors pointed out a deactivation of the insulin/IGF-1 signaling (IIS) pathway as the most probable mechanism [121,122]. D-pinitol may reduce the cellular levels of the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate (PIP3), a compound structurally related to D-pinitol that is capable to inhibit dFOXO (single *Drosophila melanogaster* forkhead box O transcription factor). Then, as dFOXO plays important functions in cell growth, proliferation, differentiation and longevity, D-pinitol facilitates its activation through reduction of its inhibitor PIP3. Hada et al. [120,123]

demonstrated that the activation of dFOXO by D-pinitol was acquired by means of the S6K and JNK signalling pathways. Furthermore, a reduction of the inflammatory response, closely related to aging, it was concluded that D-pinitol has great potential to be used as a functional ingredient with anti-aging properties [120]. Consequently, the National Institute of Advanced Industrial Science and Technology (AIST) associated with Tsujiko Co. Ltd., in Japan [124], as well as at Dermalab Co. Ltd., in Korea [125,126] have protected compositions containing D-pinitol with anti-aging properties.

Meliorative of Alzheimer's disease

Alzheimer's disease is a serious neurodegenerative condition that provokes a progressive deteriorated status of dementia in which synapses are lost [127,128]. nowadays this illness, that affects 13% of people older than 65 in developing countries, is untreatable and fatal [127]. compounds directed to reduce beta Amyloid (A β) peptide formation and to facilitate A β plaques dissolution are of principal interest, as it is the case for D-pinitol [127,128], a molecule with a high potential for treating this disease [127-137]. D-pinitol has demonstrated improving activity in preclinical models of Alzheimer's disease, making this compound an excellent candidate as a therapeutic agent for this malignancy. D-pinitol, also known as NIC5-15 in clinical trials, is considered a selective γ -secretase modulator (SGSM) that is the general denomination used to identify those molecules that are selectively capable to block the amyloid precursor protein (APP) without interfering with other signalling pathways. Concretely, D-pinitol is alleged to modulate γ -secretase and to reduce A β production, although these findings are still in a preliminary stage [127]. Pasinetti in the U.S.A. [135-136] and McLaurin in Europe [137] have patented compositions and uses of D-pinitol for treating Alzheimer's disease.

Conclusion

The pinitol is the natural occurring compound which was isolated from various plants of family Pinaceae, Asteraceae, Caryophyllaceae, Zygophyllaceous, Cupressaceae, Aristolochiaceae and Sapindaceae. Various studies have been performed & the result came out which conclude that the pinitol possess various pharmacological

activities such as anti-diabetic, anti-cancer, hepatoprotective, antioxidant, anti-osteoporosis, anti-aging etc [77]. The studies carried by Goel et al. brings up with the conclusion that d-pinitol should be better substituent for the treatment of diabetes type-2 due to its ability of to stimulate the mobility of Glucose Transporter 4 (GLUT4), which according to its sensitivity to insulin, plays an important role in the regulation of glucose transportation to the skeletal muscle and the adipose tissue[78].

Other studies have been also performed by Hada et al. showed that D-pinitol treatment considerably extended life span of *Drosophila melanogaster*, reducing oxidative stress and improving health, with evident benefits in locomotion [106].

Pasinetti in the U.S.A. [135-136] and McLaurin in Europe [137] have patented compositions and uses of D-pinitol for treating Alzheimer's disease & reported that D-pinitol has demonstrated improving activity in preclinical models of Alzheimer's disease, making this compound an excellent candidate as a therapeutic agent for this malignancy.

Liu et al. in their research work proven and identified that the D-pinitol is capable to inhibit the formation of osteoclasts induced by RANKL. Specifically, this inositol exerts this effect through the p38/JNK and NF- κ B pathways. In conclusion, D-pinitol has potential to be used for treatment and prevention of osteoporosis [118]. Lee et al. found that D-pinitol reduced the increased levels of the Th2 cytokine IL-4, a result corroborated by Chauhan et al. and both of them come up with a conclusion that d-pinitol also posse immune suppressant activity [115,119].

National Cancer Institute carried out the set of studies and found that D-pinitol reduces the progress and attack of certain prostate cancer cells in vitro at non-cytotoxic concentrations [93,94]. Also, D-pinitol has demonstrated preventive efficacy against breast cancer induced in rats [97,98] as well as tumour-growth inhibitory activity through the modulation of the balance between inflammatory cytokines, hormones, tumour markers, lipids and other biochemical processes [99,100], finally resulting in the growth retardation of tumour cells [101]. The mode of action of the D-pinitol to exert its anti-cancer

biological activity has been suggested to be the active blocking of the Nuclear Factor kappa B (NF- κ B) pathway.

The compilation of above literature review enlightens the points that the d-pinitol an active member of family inositol has a potent anti-diabetic & anti-cancer activity which must be a better therapeutic substituent for the treatment of the above mention disease in compare with the existing drugs with lesser side effects.

References

- 1 Sanz, M. L.; Martínez-Castro, I.; Moreno-Arribas, M. V. (2008). "Identification of the origin of commercial enological tannins by the analysis of monosaccharides and polyalcohols". *Food Chemistry*. 111 (3): 778.
- 2 Microbial oxidation in synthesis: A six step preparation of (+/-)-pinitol from benzene, S. V. Ley et al., *Tetrahedron Lett.* Volume 28, 1987, Pages 225.
- 3 .Anderson, A. B.; MacDonald, D. L.; Fischer, H. O. L. (1952). "The Structure of Pinitol". -*Journal of the American Chemical Society*. 74 (6): 1479.
- 4 Hudlicky T, Rulin F, Tsunoda T, et al. (1991) Biocatalysis as a rational approach to enantiodivergent synthesis of highly oxygenated compounds: (+)- and (-)-Pinitol and Other Cyclitols. *Isr J Chem* 31: 229–238.
- 5 Ley SV, Sternfeld F (1989) Microbial oxidation in synthesis: Preparation of (+)- and (-)-pinitol from benzene. *Tetrahedron* 45: 3463–3476.
- 6 .Nasar-Abbas SM, E-Huma Z, Vu T, et al. (2016) Carob Kibble: A Bioactive-Rich Food Ingredient. *Compr Rev Food Sci Food Saf* 15: 63–72.
- 7 Bhat KA, Shah BA, Gupta KK, et al. (2009) Semi-synthetic analogs of pinitol as potential inhibitors of TNF- α cytokine expression in human neutrophils. *Bioorg Med Chem Lett* 19: 1939–1943.
- 8 Anderson AB, MacDonald DL, Fischer HOL (1952) The structure of pinitol. *J Am Chem Soc* 74: 1479–1480.

- 9 Posternak T (1936) Recherches dans la série des cyclitols III. Sur la configuration des inosites actives. *HelvChim Acta* 19: 1007–1010
- 10 Catelani G, D'Andrea F, Griselli A, et al. (2008) A new stereoselective approach to a selectively protected derivative of D-pinitol and its evaluation as alpha-L-rhamnopyranose mimetic. *Tetrahedron Lett* 49: 4534–4536.
- 11 Dowd M, Stevens E (2002) The crystal structures of D-Pinitol and 1-Quebrachitol by low-temperature X-ray diffraction. *J Carbohydr Chem* 21: 373–383.
- 12 Dowd MK, Stevens ED, Experimental Crystal Structure Determination. CCDC 172582, 2014. Available from: <https://dx.doi.org/10.5517/cc5sl5p>.
- 13 Anderson I, (1972) The cyclitols, In: Pigman W, Horton D. Eds. *The Carbohydrates*, 2nd ed., New York and London: Academic Press, Inc., Vol. 1A Chemistry and Biochemistry.
- 14 Poongothai G, Sripathi SK (2013) A review on insulinomimetic pinitol from plants. *Int J Pharm Bio Sci* 4: 992–1009.
- 15 Al-Suod H, Lior M, Ratiu IA, et al. (2016) A window on cyclitols: Characterization and analytics of inositols. *Phytochem Lett* 20: 507–519. *AIMS Agriculture and Food* Volume 3, Issue 1, 41
- 16 Labed A, Ferhat M, Labed-Zouad I, et al. (2016) Compounds from the pods of *Astragalus armatus* with antioxidant, anticholinesterase, antibacterial and phagocytic activities. *Pharm Biol* 54: 3026–3032.
- 17 Lahuta LB, Ciak M, Rybinski W, et al. (2017) Diversity of the composition and content of soluble carbohydrates in seeds of the genus *Vicia* (Leguminosae). *Genet Resour Crop Evol* 2017: 1–14.
- 18 Ravi A, Alvala M, Sama V, Kalle AM, Irlapati VK, Reddy BM. Anticancer activity of *Pupalialappacea* on chronic myeloid leukemia K562 cells. *J Pharm Sci* 2012;86:1–10.
- 19 Phillips DV, Dougherty DE, Smith AE (1982) Cyclitols in soybean. *J Agric Food Chem* 30: 456–458.
- 20 Adinarayana D, Ramachandraiah P (1985) C-Glycosylphenolics from *Rhynchosiasuaveolens*. *J Nat Prod* 48: 156–157.
- 21 Plouvier Victor, Pinitol of legumes, *Compt. Rend*, 230: 125-126, (1950).
- 22 Sharma N, Verma MK, Gupta DK, et al. (2016) Isolation and quantification of pinitol in *Argyrobium roseum* plant, by ¹H-NMR. *J Saudi Chem Soc* 20: 81–87.
- 23 . Parveen, Nazneen Khan, Nizam U, Inoue T and Sakurai M, Ethyl brevifolin carboxylate and other constituents from *Acer oblongum* leaves, *Phytochemistry*, 27 (12): 3990-3991, (1988).
- 24 98 Lopes, Lucia Maria Xavier, Martins, Jose Antonio, Piasentin and Ricardo Marcelo, Polar constituents of *Aristolochiaceae*, *EcleticaQuimica*, 16: 63-80, (1991).
- 25 99. Papaj Daniel R, Feeny Paul, SachdevGupta Kusum and Rosenberry Lorraine, D-(+)-Pinitol, an oviposition stimulant for the pipevine swallowtail butterfly, *Battus philenor*, *Journal of Chemical Ecology*, 18 (5): 799-815, (1992).
- 26 100. Lopes Lucia MX and Humpfer Eberhard, 8-Benzylberbine and N-oxide alkaloids from *Aristolochia gigantea*, *Phytochemistry*, 45 (2): 431-435, (1997).
- 27 101 Francisco, Mauricio C, Nasser, Ana Lucia M and Lopes Lucia MX, Tetrahydroisoquinoline alkaloids and 2-deoxyribonolactones from *Aristolochia arcuata*, *Phytochemistry*, 62 (8): 1265- 1270, (2003).
- 28 102. Yu Li-Li, Huang Rong, Lv Yu-Ping, Zhao Yong and Chen Yegao, A new biflavonoid from *Aristolochia contorta*, *Pharmazie*, 60 (10): 789-791, (2005).

- 29 103. Plouvier, Victor, A new cyclitol, I-pinitol, isolated from *Artemisia dracunculus*, *Compt. Rend*, 243: 1913-1915, (1956).
- 30 104. Tan RX, Lu H, Wolfender JL, Yu TT, Zheng WF, Yang L, Gafner S and Hostettmann K, Mono- and sesquiterpenes and antifungal constituents from *Artemisia* species, *Planta Medica*, 65 (1): 64-67, (1999).
- 31 Aboutabl EA, Fathy FI and Sleem AA, A contribution to the phytoconstituents and bioactivities of *Artemisia vulgaris* L. cultivated in Egypt, *Egyptian Journal of Biomedical Sciences*, 21: 245-259, (2006).
- 32 Rao C. Venkata and Gunasekar D, Chemical examination of *Cardiospermum halicacabum*, Linn, *Acta Ciencia Indica Chemistry*, 13 (3): 169-170, (1987).
- 33 Plouvier, Victor, Presence of pinitol in Caryophyllaceae and in related families, *Compt. Rend*, 239: 1678-1680, (1954).
- 34 Plouvier, Victor, Pinitol in the Caryophyllaceae, Magnoliaceae, and plants of neighboring families, *Compt. Rend*, 244: 382-385, (1957).
- 35 Dominguez XA, Escarria R Saul and Butruille, Daniel, p-Hydroxybenzaldehyde in the *Cordia boisieri* fruit, *Phytochemistry*, 12 (12): 2996, (1973).
- 36 Dominguez XA, Escarria S and Butruille D, Dimethyl-3, 4'-kaempferol of *Cordia boissieri*, *Phytochemistry*, 12 (3): 724-725, (1973).
- 37 Ohashi Hideo, Goto Tomoo, Imai Takanori and Yasue Moritami, Accumulation and distribution of extractives in the living stem of Sugi (*Cryptomeria japonica* D. Don.), *Gifu Daigaku Nogakubu Kenkyu Hokoku*, 53: 301-314, (1988).
- 38 Escarria R Saul, Torrenegra Ruben Dario and Angarita, Benjamin, Colombian plants of the *Gnaphalium* genus (I), *Revista Latinoamericana de Quimica*, 8 (3): 148, (1977).
- 39 Escarria R Saul, Torrenegra Ruben Dario and Angarita, Benjamin, Colombian plants of the genus *Gnaphalium*, *Phytochemistry*, 16 (10): 1618, (1977).
- 40 Cerantola Stephane, Bessieres Marie-Anne, Magne Christian and Deslandes Eric, Occurrence of the unusual amino acid N5-(hydroxymethyl-2,5-dihydro-2-furyl)-L-allo- γ -hydroxyglutamine in *Honkenyapepoides* (L.) Ehrh, *Biochemical Systematics and Ecology*, 33 (11): 1187-1189, (2005). 33 (11): 1187-1189, (2005).
- 41 Proksa B, Vadkerti A and Belan J, Cyclitols and monosaccharides of horse chestnut pericarps, *Pharmazie*, 46 (2): 155-156, (1991).
- 42 Murakeozy Eva P, Smirnoff Nicholas, Nagy Zoltan and Tuba Zoltan, Seasonal accumulation pattern of pinitol and other carbohydrates in *Limonium gmelini* subsp. *Hungarica*, *Journal of Plant Physiology*, 159(5): 485-490, (2002).
- 43 Balabanova-Radonova E, Georgieva Ya and Mondeshka, D, Structure of certain *Lychnis coronaria* L. leaf components, *Doklady Bolgarskoi Akademii Nauk*, 35 (4): 463-466, (1982).
- 44 Popp, Marianne, Chemical composition of Australian mangroves. II. Low molecular weight carbohydrates, *Zeitschrift fuer Pflanzenphysiologie*, 113 (5): 411-421, (1984).
- 45 De Sousa, Jose Rego, Demuner, Antonio Jacinto, Pedersoli, Jose Luiz, Afonso and Ana Maria Miranda. Guine: medicinal or poisonous herb? *Ciencia e Cultura*, 39(7): 645-646, (1987).
- 46 Adhikari SK, Bell RA and Harvey WE, Cyclitols from the heartwood of *Phyllocladu strichomanoides*, *Journal of the Chemical Society*, 2629-2631, (1962).
- 47 .Leite de Almeida, M. Elita and Gottlieb Otto, The chemistry of Brazilian

- Leguminosae. 53. Further isoflavones from *Pterodon apparicioi*, *Phytochemistry*, 14 (12): 2716, (1975).
- 48 Peng Junpeng, Qiao Yanqiu, Zhang Xianzhi and Chen Peng, Studies on the bio-active components from hardwoods of *rhamnagilgitica*, *Zhongguo Yaowu Huaxue Zazhi*, 6 (2): 114-116, (1996).
- 49 . Lakshmi V, Gupta P, Tiwari P and Srivastava AK, Antihyperglycemic activity of *Rhizophora apiculata* Bl. in rats, *Natural Product Research, Part B: Bioactive Natural Products*, 20 (14): 1295-1299, (2006).
- 50 Naidoo Lovina A, Drewes Siegfried E, Van Staden J and Hutchings Anne, Exocarpic acid and other compounds from tubers and inflorescences of *Sarcophytes anguinea*, *Phytochemistry*, 31 (11): 3929-3931, (1992).
- 51 Anderson Arthur B, Riffer Richard and Wong Addie, Chemistry of the genus *Sequoia*. V. Cyclitols from the heartwood of *Sequoia gigantea*, *Phytochemistry*, 7 (8): 1367-1371, (1968).
- 52 Anderson Arthur B, Riffer Richard and Wong Addie. Chemistry of the genus *Sequoia*. VI. The cyclitols present in heartwood of *Sequoia sempervirens*, *Phytochemistry*, 7 (10): 1867-1870, (1968).
- 53 Achenbach Hans, Huebner Harald, Brandt Wolfgang and Reiter Melchoir, Cardioactive steroid saponins and other constituents from the aerial parts of *Tribulus cistoides*, *Phytochemistry*, 35 (6): 1527-1543, (1994).
- 54 Achenbach Hans, Huebner Harald and Reiter Melchior, Cholestane- and pregnane-type glycosides from the roots of *Tribulus cistoides*, *Phytochemistry*, 41 (3): 907-917, (1996).
- 55 Abdel-Hameed El-Sayed S, El-Nahas Hanan A, El-Wakil Eman A and Ahmed Wafaa S, Cytotoxic cholestane and pregnane glycosides from *Tribulus macropterus*, *Zeitschrift fuer Naturforschung C: Journal of Biosciences*, 62 (5/6): 319-325, (2007).
- 56 Cuellar M. Jesus, Giner Rosa M, Recio M. Carmen, Just M. Jose, Manez Salvador, Cerda M, Hostettmann Kurt and Rios Jose-Luis. Zanthasaponins A and B, Antiphospholipase A2 Saponins from an Anti-inflammatory Extract of *Zanthaafricana* Root Bark, *Journal of Natural Products*, 60 (11): 1158-1160, (1997).
- 57 Msonthi Jerome, Hostettmann Kurt, Cuellar Maria Jesus, Giner Rosa Maria, Recio Maria Del Carmen, Just Maria Jose, Manez Salvador, Rios Jose Luis and Bilia Anna Rita, Three New Oleanane Saponins from *Zanha Africana*, *Journal of Natural Products*, 60(2), 191-194, (1997).
- 58 Ley SV, Sternfeld F, Taylor S (1987) Microbial oxidation in synthesis: A six step preparation of (+)-Pinitol from benzene. *Tetrahedron Lett* 28: 225-226.
- 59 Hudlicky T, Price JD, Rulin F, et al. (1990) Efficient and enantiodivergent synthesis of (+)- and (-)-pinitol. *J Am Chem Soc* 112: 9439-9440.
- 60 Martin-Lomas M, Rademacher TW, Caro HN, et al. (2001) Alkylated inositolglycans and their use. Worldwide patent WO 0185747(A1).
- 61 Ishiki M, Klip A (2005) Minireview: recent developments in the regulation of glucose transporter-4 traffic: New signals, locations, and partners. *Endocrinology* 146:5071-5078.
- 62 Yap A, Nishiumi S, Yoshida KI et al (2007) Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives. *Cytotechnology* 55:103-108.
- 63 Bates SH, Jones RB, Bailey CJ (2000) Insulin-like effect of pinitol. *Br J Pharmacol* 130:1944-1948.
- 64 Dang NT, Mukai R, Yoshida KI et al (2010) D-pinitol and myo-inositol stimulate translocation of glucose

- transporter 4 in skeletal muscle of C57BL/6 mice. *BiosciBiotechnolBiochem* 74:1062–1067.
- 65 Lin TH, Tan TW, Tsai TH, et al. (2013) D-pinitol inhibits prostate cancer metastasis through inhibition of α V β 3 integrin by modulating FAK, c-Src and NF- κ B pathways. *Int J Mol Sci* 14: 9790–9802.
- 66 Streeter JG (1980) Carbohydrates in soybean nodules: II. Distribution of compounds in seedlings during the onset of nitrogen fixation. *Plant Physiol* 66: 471–476.
- 67 Gao Y, Zhang M, Wu T, et al. (2015) Effects of D-pinitol on insulin resistance through the PI3K/Akt signaling pathway in type 2 diabetes mellitus rats. *J Agric Food Chem* 63: 6019–6026.
- 68 Liu SC, Chuang SM, Tang CH (2012) D-pinitol inhibits RANKL-induced osteoclastogenesis. *Int Immunopharmacol* 12: 494–500.
- 69 Zhou Y, Park CM, Cho CW, et al. (2008) Protective effect of pinitol against D-galactosamine-induced hepatotoxicity in rats fed on a high-fat diet. *BiosciBiotechnolBiochem* 72: 1657–1666.
- 70 Shin YC, Jeon JY (2004) The physiological activities of pinitol isolated from soybean. *Food Ind Nutr* 30: 2680–2688.
- 71 Choi MS, Lee MK, Jung UJ, et al. (2009) Metabolic response of soy pinitol on lipid-lowering, antioxidant and hepatoprotective action in hamsters fed-high fat and high cholesterol diet. *Mol Nutr Food Res* 53: 751–759.
- 72 Rawal LB, Tapp RJ, Williams ED, et al. (2012) Prevention of type 2 diabetes and its complications in developing countries: A review. *Int J Behav Med* 19: 121–133.
- 73 Rathmann W, Giani G (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. *Diabetes Care* 27: 1047–1053.
- 74 Martin-Lomas M, Rademacher TW, Caro HN, et al. (2001) Alkylated inositolglycans and their use. Worldwide patent WO 0185747(A1).
- 75 Ostlund RE, Sherman WR (1998) Pinitol and derivatives thereof for the treatment of metabolic disorders. United States patent US 5827896(A).
- 76 Larner J, Price J, Picariello T, et al. (1997) Method of treating defective glucose metabolism using synthetic insulin substances. United States patent US 5652221(A).
- 77 Koon MH (2013) Combination of pinitol and natural product for treating diabetes mellitus. Korean patent KR 20130017864(A).
- 78 Koon MH (2013) Combination of pinitol and drug for treating diabetes mellitus. Korean patent KR 20130017859(A).
- 79 Jun JG, Jun YJ, Kim JJ, et al. (2004) Use of chiro-inositol or pinitol for prevention of oxidative damage and prophylaxis composition for diabetic complications containing the chiro-inositol or pinitol. Korean patent KR 20040051455(A).
- 80 Dang NT, Mukai R, Yoshida K, et al. (2010) D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. *BiosciBiotechnolBiochem* 74: 1062–1067.
- 81 Holman GD, Kasuga M (1997) From receptor to transporter: Insulin signalling to glucose transport. *Diabetologia* 40: 991–1003.
- 82 White MF (1997) The insulin signaling system and IRS proteins. *Diabetologia* 40: S2–S17.
- 83 Huang LC, Fonteles MC, Houston DB, et al. (1993) Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin diabetic rats. *Endocrinology* 132: 652–657.

- 84 . PI3 Kinase/AktSignaling Pathway, In: Cell Signaling Technology. Available from: <https://www.cellsignal.com/contents/science-pathway-research-pi3k-akt-signaling-resources/pi3k-akt-signaling-pathway/pathways-akt-signaling>
- 85 Sivakumar S, Palsamy P, Subramanian SP (2010) Impact of D-pinitol on the attenuation of proinflammatory cytokines, hyperglycemia-mediated oxidative stress and protection of kidney tissue ultrastructure in streptozotocin-induced diabetic rats. *Chem Biol Interact* 188: 237–245.
- 86 Rengarajan T, Nandakumar N, Rajendran P, et al. (2014) D-pinitol promotes apoptosis in MCF-7 cells via induction of p53 and Bax and inhibition of Bcl-2 and NF-kB. *Asian Pac J Cancer Prev* 15: 1757–1762.
- 87 Rengarajan T, Nandakumar N, Rajendran P, et al. (2015) D-pinitol mitigates tumor growth by modulating interleukins and hormones and induces apoptosis in rat breast carcinogenesis through inhibition of NF-kB. *J PhysiolBiochem* 71: 191–204.
- 88 Fentiman IS (2001) Fixed and modifiable risk factors for breast cancer. *Int J Clin Pract* 55: 527–530.
- 89 Parkin DM, Bray F, Ferlay J, et al. (2001) Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 94: 153–156.
- 90 Mundy GR (2002) Metastasis: Metastasis to bone: Causes, consequences and therapeutic opportunities. *Nat Rev Cancer* 2: 584–593.
- 91 Bryant RJ, Hamdy FC (2008) Screening for prostate cancer: An update. *Eur Urol* 53: 37–44.
- 92 Ernst DS, Hanson J, Venner PM (1991) Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. *J Urol* 146: 372–376.
- 93 Lin TH, Tan TW, Tsai TH, et al. (2013) D-pinitol inhibits prostate cancer metastasis through inhibition of α V β 3 integrin by modulating FAK, c-Src and NF-kB pathways. *Int J Mol Sci* 14: 9790–9802.
- 94 Jayasooriya R, Kang CK, Park SR, et al. (2015) Pinitol suppresses tumor necrosis factor- α -induced invasion of prostate cancer LNCaP cells by inhibiting nuclear factor-kB-Mediated matrix metalloproteinase-9 expression. *Trop J Pharm Res* 14: 1357–1364.
- 95 Ayala GE, Dai H, Ittmann M, et al. (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. *Cancer Res* 64: 6082–6090.
- 96 Nakamachi H, Suzuki H, Akakura K, et al. (2002) Clinical significance of pulmonary metastases in stage D2 prostate cancer patients. *Prostate Cancer Prostatic Dis* 5: 159–163.
- 97 Rengarajan T, Nandakumar N, Balasubramanian MP (2013) D-pinitol prevents rat breast carcinogenesis induced by 7,12-dimethylbenz (a) anthracene through inhibition of Bcl-2 and 58 AIMS Agriculture and Food Volume 3, Issue 1, 41–63.
- 98 . Kim YS, Park JS, Kim MJ, et al. (2014) Inhibitory effect of D-pinitol on both growth and recurrence of breast tumor from MDA-MB-231 Cancer Cells. *Korean J Pharmacogn* 45: 174–180.
- 99 Rengarajan T, Nandakumar N, Rajendran P, et al. (2014) D-pinitol promotes apoptosis in MCF-7 cells via induction of p53 and Bax and inhibition of Bcl-2 and NF-kB. *Asian Pac J Cancer Prev* 15: 1757–1762.
- 100 Rengarajan T, Nandakumar N, Rajendran P, et al. (2015) D-pinitol mitigates tumor growth by modulating interleukins and hormones and induces apoptosis in rat breast carcinogenesis through inhibition of NF-kB. *J PhysiolBiochem* 71: 191–204.
- 101 Mundy GR (2002) Metastasis: Metastasis to bone: Causes, consequences and

- therapeutic opportunities. *Nat Rev Cancer* 2: 584–593.
- 102 Lin TH, Tan TW, Tsai TH, et al. (2013) D-pinitol inhibits prostate cancer metastasis through inhibition of α V β 3 integrin by modulating FAK, c-Src and NF- κ B pathways. *Int J Mol Sci* 14: 9790–9802.
- 103 Lechertier T, Hodivala-Dilke K (2012) Focal adhesion kinase and tumour angiogenesis. *J Pathol* 226: 404–412.
- 104 Hwangbo C, Kim J, Lee JJ, et al. (2010) Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase C α and the PDZ adapter protein p120Cas. *Cancer Res* 70: 1645–1655.
- 105 Boukerche H, Su ZZ, Prévot C, et al. (2008) p120Cas promotes metastasis in human melanoma cells by activating c-Src. *Proc Natl Acad Sci USA* 105: 15914–15919.
- 106 Rahal A, Kumar A, Singh V, et al. (2014) Oxidative stress, pro-oxidants, and antioxidants: The interplay. *Biomed Res Int* 2014: 761264.
- 107 Sivakumar S, Palsamy P, Subramanian SP (2010) Attenuation of oxidative stress and alteration of hepatic tissue ultrastructure by D-pinitol in streptozotocin-induced diabetic rats. *Free Radic Res* 44: 668–678.
- 108 Sivakumar S, Subramanian SP (2009) Pancreatic tissue protective nature of D-pinitol studied in streptozotocin-mediated oxidative stress in experimental diabetic rats. *Eur J Pharmacol* 622: 65–70.
- 109 Magielse J, Arcoraci T, Breynaert A, et al. (2013) Antihepatotoxic activity of a quantified *Desmodium adscendens* decoction and D-pinitol against chemically-induced liver in rats. *J Ethnopharmacol* 146: 250–256.
- 110 Keppler D, Lesch R, Reutter W, et al. (1968) Experimental hepatitis induced by D-galactosamine. *Exp Mol Pathol* 9: 279–290.
- 111 Gleich GJ, Kita H (1997) Bronchial asthma: Lessons from murine models. *Proc Natl Acad Sci USA* 94: 2101–2102.
- 112 Kim JC, Shin JY, Shin DH, et al. (2005) Synergistic anti-inflammatory effects of pinitol and glucosamine in rats. *Phytother Res* 19: 1048–1051.
- 113 Lee JS, Lee CM, Jeong YI, et al. (2007) D-pinitol regulates Th1/Th2 balance via suppressing Th2 immune response in ovalbumin-induced asthma. *FEBS Lett* 581: 57–64.
- 114 Lee JS, Jung ID, Jeong YI, et al. (2007) D-pinitol inhibits Th1 polarization via the suppression of dendritic cells. *Int Immunopharmacol* 7: 79–804.
- 115 Chauhan PS, Gupta KK, Bani S (2011) The immunosuppressive effects of *Achyrocline satureioides* and pinitol in experimental animals. *Int Immunopharmacol* 11: 286–291.
- 116 Goltzman D (2002) Discoveries, drugs and skeletal disorders. *Nat Rev Drug Discov* 1: 784–796.
- 117 Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. *Science* 289: 1508–1514.
- 118 Jaerang R, Hyeon-Koon M (2010) Composition for prevention or treatment of bone metabolism disorder comprising D-pinitol as an active ingredient. Chinese patent CN 101808628(A).
- 119 Kirkwood TB, Austad SN (2000) Why do we age? *Nature* 408: 233–238.
- 120 Hada B, Yoo MR, Seong KM, et al. (2013) D-chiro-inositol and pinitol extend the life span of *Drosophila melanogaster*. *J Gerontol* 68: 226–234.
- 121 Bartke A, Chandrasekar V, Dominici F, et al. (2003) Insulin-like growth factor 1 (IGF-1) and aging: Controversies and new insights. *Biogerontology* 4: 1–8.
- 122 Van-Heemst D (2010) Insulin, IGF-1 and longevity. *Aging Dis* 1: 147–157.
- 123 Chung HY, Kim HJ, Kim JW, et al. (2001) The inflammation hypothesis of aging: Molecular modulation by calorie

- restriction. *Ann N Y Acad Sci* 928: 327–335.
- 124Ishida M, Suzuki T, Tsuji A (2015) Biological clock adjusting agent. Japanese patent JP 2015140305(A).
- 125Choi SK, Park KD, Kim DA, et al. (2013) Preparation method for *Ceratonia siliqua* fruit extract and cosmetic composition for anti-aging comprising the same. Korean patent KR 101339915(B1).
- 126Choi SK, Park KD, Kim DA, et al. (2015) Cosmetic composition for anti-aging comprising *Ceratonia siliqua* fruit extract. Korean patent KR 20150060004(A).
- 127Folch J, Petrov D, Etcheto M, et al. (2016) Current research therapeutic strategies for Alzheimer's disease treatment. *Neural Plast* 2016: 1–15.
- 128Pitt J, Thorner M, Brautigan D, et al. (2013) Protection against the synaptic targeting and toxicity of Alzheimer's-associated A β oligomers by insulin mimetic chiro-inositols. *FASEB J* 27: 199–207.
- 129Wischnik CM, Harrington CR, Storey JMD (2014) Tau-aggregation inhibitor therapy for Alzheimer's disease. *Biochem Pharmacol* 88: 529–539.
- 130Shea TB, Remington R (2015) Nutritional supplementation for Alzheimer's disease? *Curr Opin Psychiatry* 28: 141–147.
- 131Amirrad F, Bousoik E, Shamloo K, et al. (2017) Alzheimer's disease: Dawn of a new era? *J Pharm Pharm Sci* 20: 184–225.63 *AIMS Agriculture and Food* Volume 3, Issue 1, 41–63.
- 132Hung SY, Fu WM (2017) Drug candidates in clinical trials for Alzheimer's disease. *J Biomed Sci* 24: 1–12.
- 133Acton QA (2013) Therapies and treatments, In: *Neurodegenerative diseases: New insights for the healthcare professional*, Georgia: ScholarlyEditions, 203–204.
- 134Yates P, Woodward M (2017) Drug treatments in development for Alzheimer's disease, In: Ames D, O'Brien JT, Burns A. Editors, *Dementia*, 5 Eds., New York: CRC Press, 559.
- 135Pasinetti GM (2006) Compositions and methods for treating Alzheimer's disease and related disorders and promoting a healthy nervous system. United States patent US 2006/0111450A1.
- 136Pasinetti GM (2013) Compositions and methods for treating Alzheimer's disease and related disorders and promoting a healthy nervous system. United States patent US 2013/0123370A1.
- 137.McLaurin J (2010) Methods of preventing, treating and diagnosing disorders of protein aggregation. European patent EU 2153829A1.

Cite this article as:

Srivastava K., Tiwari M., Dubey A. and Dwivedi A. (2020). D-Pinitol - A Natural Phytomolecule and its Pharmacological effect, *Int. J. of Pharm. & Life Sci.*, 11(5): 6609-6623.

Source of Support: Nil

Conflict of Interest: Not declared

For reprints contact: ijplsjournal@gmail.com